Proposed EV–mitochondria network as target for age-related testosterone deficiency
The abstract proposes that Leydig cells exchange mitochondria with testicular macrophages via extracellular vesicles, that this network breaks down in three ways during aging, and that the breakdown may drive late-onset hypogonadism. Diagnostic markers and therapies are proposed, not tested. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract proposes that Leydig cells export vesicles with defective mitochondria to CD206 macrophages and import vesicles with healthy mitochondria from MHCII macrophages. [1]
According to the abstract, aging disrupts this network on the donor side, the scavenger side and in communication, which is proposed to drive late-onset hypogonadism. [1]
The abstract proposes INSL3, EV-miRNA signatures and mtDNA mutation burden for early diagnosis and MSC-EVs, NAD precursors and TREM2 activation for targeted therapy. [1]
The source at a glance
- Study type / format
- Abstract of a proposed mechanistic framework and therapeutic-target review
- Population / context
- Leydig cells and testicular macrophages in the proposed model; no human participants are described.
- Summary based on
- Study abstract
- Original publication
- June 22, 2026
Proposed EV mitochondrial exchange in Leydig cells
The abstract describes a proposed system in which Leydig cells send vesicles carrying defective mitochondria to CD206 macrophages for clearance (scavenger pathway) and take up vesicles with healthy mitochondria from MHCII macrophages (donor pathway). It contrasts this with the usual focus on quality control inside the cell. This is a proposed model, not a demonstrated human treatment target.
Supporting source [1]
Three proposed aging-related disruptions of the network
According to the abstract, aging disrupts the network in three ways: donor-side collapse (less PGC-1α, Drp1 predominating over Mfn2, NAD depletion), scavenger-side obstruction (less TREM2, impaired phagosome-lysosome fusion) and communication uncoupling from decay of the VCAM1/ITGβ1 axis. These failures are said to lead to a mitochondrial quality crisis, steroidogenic enzyme dysfunction and progressive loss of Leydig cells, which the authors propose initiates and drives late-onset hypogonadism. Individual differences in network efficiency are said to shape susceptibility, and the point of decompensation is proposed as the shift from a compensated state to clinical disease.
Supporting source [1]
Proposed diagnostic markers and therapies, untested
The abstract suggests that closer study of this network could support early diagnosis using INSL3, EV-miRNA signatures and mtDNA mutation burden, and targeted therapy using MSC-EVs, NAD precursors and TREM2 activation. These are proposals for future strategies; the abstract reports no patients, no comparison groups and no outcome data, so none of these markers or treatments is shown to work.
Supporting source [1]
How to interpret this
This is an abstract only; the full text was not reviewed. It describes a proposed mechanism and proposed diagnostic and therapeutic strategies without reporting patients, study design, sample size, follow-up or outcome data. No clinical benefit is shown.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhou L, Tian X, Wang X, Lan X, Wang M, Li J, Dong L, Yu X, Yang F. · europepmc.org · June 22, 2026